Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Alnylam Pharmaceuticals Inc
EPS (Diluted)
Alnylam Pharmaceuticals Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
EPS (Diluted)
-$2
|
CAGR 3-Years
33%
|
CAGR 5-Years
23%
|
CAGR 10-Years
7%
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$0
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-26%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$7
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
-$2
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$38
|
CAGR 3-Years
-19%
|
CAGR 5-Years
16%
|
CAGR 10-Years
29%
|
|
Alnylam Pharmaceuticals Inc
Glance View
In the heart of the biotechnology revolution, Alnylam Pharmaceuticals Inc. has been a pioneering force, transforming the landscape of medicine through its innovative use of RNA interference (RNAi) technology. Founded in 2002 and based in Cambridge, Massachusetts, the company set out on a bold mission to silence disease-causing genes by targeting RNA, the intermediary that carries genetic instructions necessary for protein synthesis. This groundbreaking approach diverges from traditional methods that focus on targeting proteins directly and instead intervenes earlier in the disease process to eliminate or reduce the proteins before they can wreak havoc on the body. Fueled by extensive research and a robust pipeline, Alnylam has successfully brought several RNAi-based therapies to market, such as Onpattro and Givlaari, which address rare genetic disorders with high unmet medical needs. Alnylam's business model is centered around the commercial success of its novel therapies, partnerships with other pharmaceutical giants, and strategic collaborations for global distribution. By securing alliances with industry leaders like Sanofi and Regeneron, Alnylam has been able to expand its research capabilities and broaden its market reach. Revenue for the company is primarily driven by the sales of its approved products, which continue to grow as they gain acceptance within the medical community. Additionally, Alnylam's extensive patent portfolio and its strategic licensing agreements provide an additional revenue stream, safeguarding its innovations and ensuring it retains a competitive edge in this rapidly advancing field. Through its relentless pursuit of innovation, Alnylam continues to position itself as a trailblazer in turning the once theoretical promise of RNAi into a clinical reality.
See Also
What is Alnylam Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-2.2
USD
Based on the financial report for Dec 31, 2024, Alnylam Pharmaceuticals Inc's EPS (Diluted) amounts to -2.2 USD.
What is Alnylam Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
7%
Over the last year, the EPS (Diluted) growth was 38%. The average annual EPS (Diluted) growth rates for Alnylam Pharmaceuticals Inc have been 33% over the past three years , 23% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet